Physician profile
David N Smith
NPI 1538450028
$3,372.17
in general payments reported to CMS, 2019-2025
23 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $30.00 · 2022: $67.78 · 2023: $565 · 2024: $1,220 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.10 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $410.13 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $373.45 | 2024-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $331.19 | 2022-2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $329.43 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $227.29 | 2024-2025 | Capvaxive, Winrevair |
| Abbvie INC. | $210.52 | 2023-2025 | Avycaz, Teflaro |
| Olympus Corporation of The Americas | $203.60 | 2019 | |
| Inogen, INC. | $135.51 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Insmed, INC. | $108.81 | 2024-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $79.55 | 2020-2024 | Yupelri |
| Electromed, INC. | $67.54 | 2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $60.33 | 2024 | Glassia |
| Astrazeneca Pharmaceuticals LP | $58.31 | 2022-2024 | Tezspire, Fasenra |
| Allergan, INC. | $52.54 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $51.33 | 2025 | Ohtuvayre |
| Chiesi USA, INC. | $32.43 | 2023-2024 | Cleviprex |
| Jazz Pharmaceuticals INC. | $28.65 | 2025 | |
| Biomerieux INC | $28.38 | 2023 | Nephrocheck Liquid Control Kit |
| Paratek Pharmaceuticals, INC. | $24.06 | 2025 | Nuzyra |
| Viatris Specialty LLC | $22.45 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $16.95 | 2022 | |
| Pfizer INC. | $14.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.